Novartis’ groundbreaking cancer T-cell therapy CTL019 has won unanimous backing from advisers to the FDA, paving the way for approval in the coming months. There had been concerns that the expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback